By Dr. Mones Abu‑Asab, PhD (co‑founder of Phyloncology LLC)

Drawing on 26 years at George Washington University School of Medicine and the National Institutes of Health, Dr. Abu‑Asab introduces a bold evolutionary lens to the study of cancer. His new book, Unraveling Cancer, reexamines the disease not as a collection of genetic errors, but as a deep-rooted evolutionary imbalance arising from the fundamental architecture of eukaryotic life.

📘 Key Themes & Innovations

• Evolutionary Origin: The book begins by tracing the evolutionary emergence of the eukaryotic cell, identifying clues to why multicellularity is inherently vulnerable to oncogenesis.
• Energy-Driven Hypothesis: It challenges conventional mutation-centric views, positing instead that disruptions in cellular energy dynamics are the primary spark for tumor initiation.
• Cancer Hallmarks & Microenvironment: It synthesizes classic hallmarks—like limitless replication and angiogenesis—with modern insights into metabolic shifts, microbial interactions, and the tumor milieu.
• Oncogenic Spectrum: Cancer is presented not as a uniform entity but as a spectrum influenced by energy flux, lineage history, and environmental context.
• Metastasis & Angiogenesis: These processes are reframed through ecological and evolutionary mechanisms, underlining their dynamic and adaptive nature.
• Microbiome Link: The interplay between host microbial ecosystems and tumor development is examined, aligning with recent studies in evolutionary oncology .
• Heterogeneity & Data Analysis: Emphasizing cancer’s intrinsic heterogeneity, Dr. Abu‑Asab argues that traditional average‑based analytics fall short. He advocates for phylogenetic and heterogeneity‑compatible bioinformatic tools—such as parsimony cladistics—to uncover meaningful tumor substructures .

🎯 Why It Matters

By integrating evolutionary theory, bioenergetics, tumor ecology, and sophisticated data analytics, Unraveling Cancer offers a cohesive and layered framework. Its aim is to deepen our understanding of cancer’s origins, drive diagnostic precision, and ultimately enrich therapeutic strategies.

Bottom line: This book redefines cancer as an evolutionary and energy‐centered phenomenon. It’s an essential read for researchers, clinicians, and data scientists seeking a fresh paradigm—one grounded in cellular evolution and ecological complexity.

Why haven’t you heard of the most promising early detection and diagnostic tool for cancer?

It’s a fair question—especially given its potential to save countless lives and transform cancer diagnosis on a global scale. Think of how Apple, Amazon, and Google reshaped the world. We believe this technology can have a similar level of impact—but in the realm of healthcare.

We discovered this tool in 2005, patented it in 2007 and received the actual patent in 2014, published peer-reviewed papers, and spoke to numerous researchers. And yet, we remain largely unknown. No big-name institution or lab. Just a small team of persistent, independent researchers with a universal solution—and unwavering belief in its power.

While much of the cancer research world focuses on identifying specific biomarkers for individual cancer types—often spending decades on a single subtype—we approached cancer from a radically different angle.

We asked: What if cancer, like all life forms, followed evolutionary patterns? What if we could apply phylogenetic analysis—a method universally accepted in biology to classify animals, plants, viruses, and bacteria—to cancer itself?

That’s exactly what we did.

And it worked. Across all cancer types.

Our tool doesn’t depend on narrow biomarkers or siloed cancer classifications. It uses a proven evolutionary framework to identify cancer universally—because we believe cancer itself is an evolutionary disease.

Yet, most cancer researchers we speak to are unfamiliar with the depth and power of phylogenetics. As a result, many conversations hit a wall—not because of disagreement, but because of a gap in expertise. And this knowledge gap has likely slowed the recognition of our work.

We’ve never pitched to angel investors. We’ve never stood on a stage. We’ve sent emails, LinkedIn messages, and filled out contact forms. But those likely ended up in junk folders, dismissed as spam, or overlooked as unsolicited outreach.

Why? Because we’re full-time professionals, sole breadwinners, and believed—perhaps naively—that if you build something truly excellent and publish it, people will notice.

But here’s what we know for sure:
This technology works. It is universal. It can change the trajectory of cancer diagnosis. And all it takes is one person to see its potential—to invest, to amplify, to help us bring it to the world.

So again, we ask:
Why haven’t you heard of the best early detection and diagnostic tool for cancer?

Because no one has given it ten minutes. Yet.